

The Path to Strategic Sequencing in 3L HER2+ Metastatic Breast Cancer



Wednesday, 15 May 2024 | 11:30 – 12:30 CEST

Munich Hall, Hub27, Berlin



Sara Tolaney, MD, MPH
Boston, MA, United States
(CHAIR)



Rupert Bartsch, MD
Vienna, Austria



Carmen Criscitiello, MD, PhD
Milan, Italy

OVERVIEW

In recent years, significant advances in the treatment landscape for HER2+ metastatic breast cancer (MBC) have widened the therapeutic options. But how can we address the complexities in the decision-making process for the optimal HER2-targeted therapy sequence?

Join our expert faculty for an interactive and engaging one-hour symposium. Our experts will deep dive into the current guideline recommendations and the latest available treatment data for HER2+ MBC while discussing case-based scenarios for the clinical implementation of treatment sequencing, especially in patients with disease progression following T-DXd and those with central nervous system (CNS) involvement.

AGENDA

- | | |
|---|---|
| <p>11:30 – 11:35 Welcome
Sara Tolaney</p> <p>11:35 – 11:45 Reading the Chessboard: Transformation and opportunities in the treatment landscape of HER2+ MBC
Sara Tolaney</p> <p>11:45 – 12:00 CNS Defence: A case-based conversation about the threat of CNS involvement and clinical decision-making in HER2+ MBC
Rupert Bartsch</p> | <p>12:00 – 12:15 Moving Forward: A case-based conversation on clinical decision-making in 3L post T-DXd progression and future directions in HER2+ MBC
Carmen Criscitiello</p> <p>12:15 – 12:25 Panel Discussion and Audience Q&A
All Faculty</p> <p>12:25 – 12:30 Closing Remarks
Sara Tolaney</p> |
|---|---|